Edit Entry | Edit CV

Diwakar R Pattabiraman, PhD

Title(s)
Adjunct Assistant Professor of Molecular and Systems Biology

Department(s)
Molecular and Systems Biology

Education
PhD, Cancer Biology - University of Queensland, Australia
Postdoctoral training - Whitehead Institute for Biomedical Research (MIT), Cambridge MA

Programs
Molecular and Cellular Biology Graduate Programs
Dartmouth Cancer Center
Program in Experimental and Molecular Medicine

Websites
http://geiselmed.dartmouth.edu/raman/

Contact Information

1 Medical Center Drive
Room 602, Rubin Building
Norris Cotton Cancer Center
Lebanon NH 03756

Office: 603-653-9957
Email: Diwakar.R.Pattabiraman@Dartmouth.edu

Professional Interests

Our research focuses on understanding the genetic, epigenetic, signaling and cell biological aspects of tumor progression and metastasis in carcinomas. We study the role of transitions in epithelial and mesenchymal states within carcinomas as a model of understanding intratumoral heterogeneity to develop novel ways of overcoming metastatic progression and therapy resistance.

Rotations and Thesis Projects

Epithelial-Mesenchymal Transition
Cancer Stem Cells
Intratumoral heterogeneity
Tumor Progression and Metastasis

Grant Information

4R00CA105574-03 (PI:Pattabiraman) 09/01/16 – 08/31/21
NIH NCI K99/R00 Pathway to Independence Award
Project: "Exploiting the epithelial-to-mesenchymal transition for the differentiation of cancer stem cells"
Role: PI

Pilot Project Grant (PIs: Pattabiraman & Mierke) 01/04/2018 –12/31/2018
Norris Cotton Cancer Center Developmental Funds
Project: “Developing novel inhibitors of Zeb1 to target tumor progression and therapy resistance"
Role: PI

Selected Publications
 

  • Pattabiraman DR, Bierie B, Kober KI, Thiru P, Krall JA, Zill C, Reinhardt F, Tam WL, Weinberg RA Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science. 2016 Mar 4;351(6277):aad3680. doi: 10.1126/science.aad3680 (view details in PubMed)

  • Pattabiraman DR, Weinberg RA Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy. Cold Spring Harb Symp Quant Biol. 2016;81:11-19. doi: 10.1101/sqb.2016.81.030957. Epub 2017 Jan 5 (view details in PubMed)

  • Lambert AW, Pattabiraman DR, Weinberg RA Emerging Biological Principles of Metastasis. Cell. 2017 Feb 9;168(4):670-691. doi: 10.1016/j.cell.2016.11.037 (view details in PubMed)

  • Pattabiraman DR, Weinberg RA Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014 Jul;13(7):497-512. doi: 10.1038/nrd4253 (view details in PubMed)

  • Bierie B, Pierce SE, Kroeger C, Stover DG, Pattabiraman DR, Thiru P, Liu Donaher J, Reinhardt F, Chaffer CL, Keckesova Z, Weinberg RA Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346. doi: 10.1073/pnas.1618298114. Epub 2017 Mar 7 (view details in PubMed)

  • Pattabiraman DR, McGirr C, Shakhbazov K, Barbier V, Krishnan K, Mukhopadhyay P, Hawthorne P, Trezise A, Ding J, Grimmond SM, Papathanasiou P, Alexander WS, Perkins AC, Levesque JP, Winkler IG, Gonda TJ Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood. 2014 Apr 24;123(17):2682-90. doi: 10.1182/blood-2012-02-413187. Epub 2014 Mar 4 (view details in PubMed)

  • Pattabiraman DR, Gonda TJ Role and potential for therapeutic targeting of MYB in leukemia. Leukemia. 2013 Feb;27(2):269-77. doi: 10.1038/leu.2012.225. Epub 2012 Aug 9 (view details in PubMed)

    		•